Beijing Tong Ren Tang Chinese Medicine Company Limited (FRA:TQR)
Germany
· Delayed Price · Currency is EUR 0.9700
-0.0050 (-0.51%)
At close: Apr 25, 2025, 10:00 PM CET
FRA:TQR Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,612 | 1,525 | 1,731 | 1,556 | 1,315 | Upgrade
|
| Revenue Growth (YoY) | 5.68% | -11.91% | 11.24% | 18.31% | -8.19% | Upgrade
|
| Cost of Revenue | 546.32 | 477.7 | 580.96 | 436.54 | 362.44 | Upgrade
|
| Gross Profit | 1,065 | 1,047 | 1,150 | 1,120 | 952.9 | Upgrade
|
| Selling, General & Admin | 492 | 410.29 | 341.68 | 341.68 | 307.81 | Upgrade
|
| Other Operating Expenses | -2.68 | -6.53 | -2.51 | -1.71 | -1.91 | Upgrade
|
| Operating Expenses | 491.27 | 424.95 | 345.65 | 347.49 | 309.23 | Upgrade
|
| Operating Income | 574.06 | 622.3 | 804.49 | 772.13 | 643.67 | Upgrade
|
| Interest Expense | -6.48 | -5.98 | -4.66 | -4.71 | -4.3 | Upgrade
|
| Interest & Investment Income | 57.67 | 72.88 | 20.59 | 4.38 | 21.65 | Upgrade
|
| Earnings From Equity Investments | 2.06 | -3.26 | -1.54 | 0.26 | -0.86 | Upgrade
|
| EBT Excluding Unusual Items | 627.3 | 685.94 | 818.88 | 772.06 | 660.16 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.47 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | 1.85 | 7.09 | 6.33 | 25.73 | Upgrade
|
| Pretax Income | 629.77 | 687.79 | 825.96 | 778.39 | 685.9 | Upgrade
|
| Income Tax Expense | 100.61 | 97.2 | 134.67 | 126.85 | 118.01 | Upgrade
|
| Earnings From Continuing Operations | 529.17 | 590.59 | 691.29 | 651.54 | 567.88 | Upgrade
|
| Minority Interest in Earnings | -28.89 | -50.19 | -45.42 | -43.71 | -25.43 | Upgrade
|
| Net Income | 500.28 | 540.39 | 645.88 | 607.84 | 542.46 | Upgrade
|
| Net Income to Common | 500.28 | 540.39 | 645.88 | 607.84 | 542.46 | Upgrade
|
| Net Income Growth | -7.42% | -16.33% | 6.26% | 12.05% | -2.46% | Upgrade
|
| Shares Outstanding (Basic) | 837 | 837 | 837 | 837 | 837 | Upgrade
|
| Shares Outstanding (Diluted) | 837 | 837 | 837 | 837 | 837 | Upgrade
|
| EPS (Basic) | 0.60 | 0.65 | 0.77 | 0.73 | 0.65 | Upgrade
|
| EPS (Diluted) | 0.60 | 0.65 | 0.77 | 0.73 | 0.65 | Upgrade
|
| EPS Growth | -7.42% | -16.33% | 6.26% | 12.05% | -2.46% | Upgrade
|
| Free Cash Flow | - | 438.97 | 508.94 | 753.74 | 103.17 | Upgrade
|
| Free Cash Flow Per Share | - | 0.52 | 0.61 | 0.90 | 0.12 | Upgrade
|
| Dividend Per Share | 0.350 | 0.330 | 0.330 | 0.280 | 0.240 | Upgrade
|
| Dividend Growth | 6.06% | - | 17.86% | 16.67% | 4.35% | Upgrade
|
| Gross Margin | 66.10% | 68.67% | 66.44% | 71.95% | 72.45% | Upgrade
|
| Operating Margin | 35.62% | 40.81% | 46.47% | 49.62% | 48.94% | Upgrade
|
| Profit Margin | 31.04% | 35.44% | 37.31% | 39.06% | 41.24% | Upgrade
|
| Free Cash Flow Margin | - | 28.79% | 29.40% | 48.44% | 7.84% | Upgrade
|
| EBITDA | 590.72 | 638.96 | 818.84 | 786.5 | 666.2 | Upgrade
|
| EBITDA Margin | 36.65% | 41.90% | 47.30% | 50.54% | 50.65% | Upgrade
|
| D&A For EBITDA | 16.66 | 16.66 | 14.35 | 14.37 | 22.53 | Upgrade
|
| EBIT | 574.06 | 622.3 | 804.49 | 772.13 | 643.67 | Upgrade
|
| EBIT Margin | 35.62% | 40.81% | 46.47% | 49.62% | 48.94% | Upgrade
|
| Effective Tax Rate | 15.97% | 14.13% | 16.30% | 16.30% | 17.21% | Upgrade
|
| Advertising Expenses | 112.15 | 47.39 | 19.18 | 23.58 | 16.82 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.